Allergan PlcAGN announced that a study evaluating higher doses of its facial aesthetics drug Botox for the treatment of moderate-to-severe glabellar lines, met the primary endpoint.
The study was conducted to evaluate the safety and efficacy of Botox' higher doses (40, 60, and 80-unit doses) against the current marketed 20 mg dose. Data from the study showed that patients receiving Botox (cosmetic) in 40, 60 or 80 units achieved a greater duration of treatment effect than those injected with the current dosage of 20 units.
Glabellar lines are the frown lines found between the eyebrows and the central forehead.
In the study, response rates for the 40, 60 and 80-unit groups were 32%, 30.6% and 38.5%, respectively, compared with 16% in the 20-unit group at week 24. The study clearly demonstrated that higher doses of Botox extend the treatment effect duration for glabellar lines in approximately one of three patients. Overall, higher doses of the drug were safe and well tolerated with serious adverse event (SAE) unrelated to the line of treatment.
Shares of Allergan have rallied 15.1% so far this year, comparing favorably with the industry's increase of 4.1%.
Botox's therapeutic diseases include overactive bladder, cervical dystonia and strabismus among others.
Notably, Botox is one of the key revenue catalysts for Allergan. The drug generated sales of $1.75 billion in the second half of 2018. In the chronic migraine indication, there have been concerns regarding possible new competitors to Botox with the entry of calcitonin gene-related peptide (CGRP) antibodies.
Amgen AMGN /Novartis' CGRP antibody Aimovig was launched in May while Teva's TEVA Ajovy (fremanezumab) was approved this month. Moreover, a decision on Lilly's LLY CGRP antibody Emgality (galcanezumab) is also due by September-end.
In a separate press release, the company announced that it has agreed to acquire the privately held biotech Bonti, Inc., a developer of fast-acting neurotoxin treatments for aesthetic and therapeutic applications.
Per agreement, Allergan will make an upfront payment of $195 million plus potential milestone payments, subject to certain adjustments and customary closing conditions.
The acquisition will add two phase II stage candidates, namely EB-001A (aesthetic) and EB-001T (therapeutic) to Allergan's portfolio. The main component in both programs, a botulinum neurotoxin serotype E has a two-to-four-week duration of effect, which should be an attractive offer for consumers, especially for those seeking an aesthetic treatment for the first time.
Allergan plc Price and Consensus
Allergan plc Price and Consensus | Allergan plc Quote
Zacks Rank
Allergan currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan plc (AGN): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
